Solesence, Inc., a science-driven company, develops, manufactures, and sells integrated family of technologies in the United States. The company is headquartered in Romeoville, Illinois.
| Revenue (TTM) | $60.40M |
| Gross Profit (TTM) | $16.02M |
| EBITDA | $1.80M |
| Operating Margin | -3.89% |
| Return on Equity | 5.88% |
| Return on Assets | 0.97% |
| Revenue/Share (TTM) | $0.86 |
| Book Value | $0.24 |
| Price-to-Book | 2.84 |
| Price-to-Sales (TTM) | 0.84 |
| EV/Revenue | 1.158 |
| EV/EBITDA | 23.16 |
| Quarterly Earnings Growth (YoY) | -93.50% |
| Quarterly Revenue Growth (YoY) | -11.40% |
| Shares Outstanding | $70.63M |
| Float | $18.32M |
| % Insiders | 73.11% |
| % Institutions | 6.29% |
Volatility is currently expanding
Global Award Recognizes Excellence in Service, Reliability, and Innovation ROMEOVILLE, Ill., June 18, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc.
SPF-Infused Concealer Featuring Kleair™, WHSPR™, and Chromalüm™ Recognized Across Anti-Aging, Color Cosmetics, and Compromised Skin
Solesence incurs a Q1 loss per share as shipment delays pressure revenues, even as gross margin improves and the company reaffirms its 2026 profitability targets.
Solesence, Inc. (SLSN) Q1 2026 Earnings Call Transcript
Advances implementation of Transform and Transcend strategic initiative across Operational Excellence and New Technology Commercialization ROMEOVILLE, Ill., May 12, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the first quarter ended March 31, 2026.
New platform technologies enable OTC-grade sensitive skin claims in previously inaccessible anhydrous formats and bring environmental protection deeper into the color cosmetics assortment
ROMEOVILLE, Ill., April 28, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company will report results for the first quarter of 2026 after the market opens on Tuesday, May 12, 2026, and host a conference call and webcast on the same date.
Marc James to Join Board of Directors and Serve on Audit, Compensation, and Nominating Committees ROMEOVILLE, Ill., April 27, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced the appointment of Marc James to its Board of Directors as an independent director, effective immediately.
Discover why Zacks issues an "Underperform" rating for Solesence, being the first on Wall Street to initiate coverage on the stock. Learn how margin pressure, cash flow weakness, rising leverage and execution challenges are weighing on growth.
